Rho Ventures, a multi-stage venture capital firm, today announced the promotion of two veteran team members, Hugh Browne and Medha Vedaprakash, from associate to principal. Browne joined the firm in 2008 and is based in Palo Alto, Calif. Vedaprakash joined the firm's New York office in 2007.

"Medha and Hugh have been key members of our team for several years. They bring a tremendous amount of dedication and talent to the firm, the portfolio companies they work with and the networks within their communities," said Mark Leschly, Rho Ventures managing partner.

Browne's primary investment sectors include new media, mobile and information technology. He joined Rho Ventures after spending five years at Morgan Stanley, where he focused on various principal investing and operational activities. Browne received his M.B.A. from Stanford University's Graduate School of Business.

Vedaprakash's main focus areas include new media, mobile and information technology. She joined Rho Ventures after several years of operating experience at Siemens Communications, where she was responsible for designing and leading the development of multiple products including the company's voice over cable solution. Vedaprakash received her M.B.A. from the University of Pennsylvania's Wharton School of Business.

About Rho Ventures

Rho Ventures (www.rho.com) has a multi-stage investing strategy focused on high-growth companies in large markets. Rho Ventures' investments span new media, healthcare, IT, communications, energy technology and other disruptive technologies. Rho Ventures brings nearly 30 years of venture experience, combined with its partners' deep sector expertise and its far-reaching network to assist each portfolio company. This approach has allowed Rho to participate in the growth of some of today's most innovative and successful companies, including Active Power, Capstone Turbine, Ciena, Compaq Computer, EverydayHealth.com, Gloucester Pharmaceuticals, Human Genome Sciences, IntraLinks, iVillage, MedImmune, ReachLocal, Shire Pharmaceuticals and Tacoda. Rho Ventures is currently investing from Rho Ventures VI, a $510 million fund. The firm has offices in Palo Alto, Calif., New York and Montreal, with investments across the globe.